




RealRate

PHARMACEUTICAL 2022

Immunome Inc
Rank 176 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Immunome Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Immunome Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 52% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	56,638
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,728
Liabilities, Non-Current	0
Other Assets	432
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	12
Other Net Income	493
Other Revenues	0
Property and Equipment	855
Research and Development	14,110
Selling, General and Administrative Expense	11,094

Output Variable	Value in 1000 USD
Assets	57,925
Liabilities	9,740
Expenses	25,204
Revenues	0
Stockholders Equity	48,185
Net Income	-24,711
Comprehensive Net Income	-24,711
BaseVar	46,681
ECR before Limited Liability	237%
Economic Capital Ratio	327%